Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Rezetecan and Adebrelimab in Stage III NSCLC
NCT07836543Phase 2Not yet recruiting
- Start
- Sep 2026
- Primary completion
- Dec 2029
01
Overview
Phase 2, randomised, open-label trial of trastuzumab rezetecan and adebrelimab in non-small cell lung cancer (NSCLC) (3 arms). Primary endpoint: Progression-Free Survival at 36 months. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
trastuzumab rezetecanadebrelimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07836543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07836543.